echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nuocheng Jianhua Obutinib was approved to carry out Phase II clinical studies for the treatment of MS in Poland and Ukraine

    Nuocheng Jianhua Obutinib was approved to carry out Phase II clinical studies for the treatment of MS in Poland and Ukraine

    • Last Update: 2021-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor obutinib for the treatment of multiple sclerosis (MS) clinical trial application (CTA) has been obtained by the Polish authorities and the Ukrainian Ministry of Health and With the approval of the ethics committee, phase II clinical studies will be launched in these two countries soon


    This will be a randomized, double-blind, placebo-controlled phase II clinical study to evaluate the use of abutinib in patients with relapsing-remitting multiple sclerosis (RRMS).


    According to data released by the Multiple Sclerosis International Federation (MSIF), currently more than 2.


    MS is an autoimmune central nervous system disease.


    Note: The original text has been deleted

    Reference materials:

    [1] Data source: Multiple Sclerosis International Federation (MSIF) official website https:// Data source: Frost & Sullivan analysis

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.